Completed
PHASE3
INTERVENTIONAL
NCT04844918
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
OTHER
Description:
Administered SC
Primary Outcomes
Measure:
Mean Percent Change in Body Weight
TimeFrame:
Baseline, 72 Weeks
Description:
Mean percent change in body weight was measured. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + impaired glucose tolerance (IGT) at Screening + Hyperlipidemia at Screening + non-alcoholic fatty liver disease (NAFLD) at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Measure:
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
TimeFrame:
Week 72
Description:
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Trial Information
NCT ID
NCT04844918
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025